Swiss giant Novartis’ (NYSE: NVS) Cosentyx (secukinumab) has secured another indication approval from China’s National Medical Products Administration (NMPA), this time for the treatment of moderate to severe hidradenitis suppurativa (HS). This IL-17A-targeted therapy previously gained approval in China for moderate-to-severe plaque psoriasis, ankylosing spondylitis, and active psoriatic arthritis (PsA).
Clinical Trial Basis
The NMPA’s approval is based on analyses from the Phase III SUNSHINE and SUNRISE trials. In these trials, secukinumab demonstrated rapid onset of action, with effects observed within 2 weeks, and efficacy that gradually increased until week 16, continuing until week 52.
Efficacy Results
The proportion of patients in the secukinumab group achieving hidradenitis suppurativa clinical response (HiSCR50, defined as a ≥50% reduction in the number of inflammatory lesions) was significantly higher than that in the placebo group. The drug showed significant reductions in inflammatory nodules and abscesses, and demonstrated the ability to control the recurrence of HS, offering a new treatment option for patients with this condition.-Fineline Info & Tech
Leave a Reply